Here are five points:
1. B. Riley researchers estimate Mazor will see second quarter 2018 earnings of $0.13 EPS; third quarter 2018 earnings of $0.12 EPS; and fourth quarter 2018 earnings of $0.07 EPS.
2. The firm has a “neutral” rating on Mazor with a $25 price objective.
3. Mazor has a 52-week low of $9.16 and 52-week high of $26.55.
4. The company’s 50-day moving average is $22.62, with a 200-day moving average of $22.74.
5. Mazor’s market capitalization is $535.76 million.
More articles on devices:
SeaSpine revenue drops 3.2% to $128.9M in 2016: 8 key notes
Image-guided orthopedic surgery market to grow at 7% CAGR through 2022: 5 observations
Implanet earns French patent to protect JAZZ Lock: 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
